Toleranzia AB ("Toleranzia" or the "Company") today announces the outcome of the exercise of the warrants of series TO3, which were issued in connection with the Company's issue of units during the third quarter of 2020. In total, 24 151 007 warrants of series TO3, corresponding to approximately 95.7 percent of the outstanding warrants of series TO3, were used for the subscription of 24 151 007 shares at a subscription price of SEK 1.14 per share. The exercise of the TO3 warrants will provide Toleranzia with approximately SEK 27.5 million before issue costs.

Background
The subscription period for the exercise of the warrants of series TO3 ran during the period from 1 September 2021 to 15 September 2021. The subscription price per share upon exercise of the warrants of series TO3 was set at SEK 1.14.

A total of 24 151 007 warrants of series TO3 were used to subscribe for 24 151 007 shares, meaning that approximately 95.7 percent of the outstanding warrants of series TO3 were used.

Exercised warrants have been replaced by interim shares (IA) pending registration with the Swedish Companies Registration Office. The conversion of interim shares into shares is expected to take place within approximately three (3) weeks.

Number of shares, share capital and dilution
The exercise of the TO3 warrants increases the number of shares in Toleranzia by 24 151 007 shares, from 54 346 041 to a total of 78 497 048 shares. The share capital increases by SEK 3 018 875.875, from SEK 6 793 255.125 to SEK 9 812 131.

For existing shareholders who have not exercised any warrants of series TO3, the dilution amounts to approximately 44.4 percent based on the number of shares after the exercise of the warrants of series TO3.

Comment from Charlotte Fribert, CEO:
We are extremely pleased with the good outcome of the exercise of the TO3 warrants. We see the high level of participation as evidence of the continued high level of confidence in the Company. With the injected capital, we are strengthening the financial base to pursue the development of TOL2, a new unique treatment for patients with myasthenia gravis, with high intensity. I would like to thank existing and new shareholders of Toleranzia who participated in the warrant program for their willingness to be part of the Company's exciting journey towards its first drug in the field of rare autoimmune diseases.

Advisor
Mangold Fondkommission AB is the financial advisor and Eversheds Sutherland Advokatbyrå AB is the legal advisor to Toleranzia regarding the warrants.

For questions regarding the warrants, please contact:
Mangold Fondkommission AB
Telephone: +46 8 5050 1595
E-mail: emissioner@mangold.se
 
For further information, please contact:
Charlotte Fribert - CEO, Toleranzia
Telephone: +46 763 19 98 98
Email: charlotte.fribert@toleranzia.com
www.toleranzia.com
 
About Toleranzia AB
Toleranzia AB (556877-2866) is a Swedish biotechnology company listed on Nasdaq First North Growth Market. The company develops drugs that harness the power of the immune system for the treatment of autoimmune orphan diseases. The drugs, which target the cause of the disease, can alleviate or cure the disease and not, like current treatments, merely reduce the symptoms. They have the potential to be the first long-acting or curative therapies that act specifically on the underlying cause of the autoimmune orphan disease for which they are being developed. Toleranzia's shares are listed on Nasdaq First North Growth Market and Mangold Fondkommission AB, 08-503 015 50, CA@mangold.se, is the company's Certified Adviser.